Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 10, Issue 9, Pages 1266-1271Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.9b00082
Keywords
Vaccinia-related kinases; pyridine; difluorophenol; kinase inhibitors; structure-based compound development
Categories
Funding
- Brazilian agency FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) [2013/50724-5, 2014/5087-0]
- Brazilian agency Embrapii (Empresa Brasileira de Pesquisa e Inovacao Industrial)
- Brazilian agency CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) [465651/2014-3, 400906/2014-7]
- AbbVie [1097737]
- Bayer Pharma AG [1097737]
- Boehringer Ingelheim [1097737]
- Canada Foundation for Innovation [1097737]
- Eshelman Institute for Innovation [1097737]
- Genome Canada [1097737]
- Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant] [1097737, 115766]
- Janssen [1097737]
- Merck KGaA Darmstadt Germany [1097737]
- MSD [1097737]
- Novartis Pharma AG [1097737]
- Ontario Ministry of Economic Development and Innovation [1097737]
- Pfizer [1097737]
- Takeda [1097737]
- Wellcome [1097737, 106169/ZZ14/Z]
- FAPESP [2016/25320-6, 2018/09475-5, 2018/03359-3]
- CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) [88887.146077/2017-00, 88887.136342/2017-00]
Ask authors/readers for more resources
Vaccinia-related kinases 1 and 2 (VRK1 and VRK2) are human Ser/Thr protein kinases associated with increased cell division and neurological disorders. Nevertheless, the cellular functions of these proteins are not fully understood. Despite their therapeutic potential, there are no potent and specific inhibitors available for VRK1 or VRK2. We report here the discovery and elaboration of an aminopyridine scaffold as a basis for VRK1 and VRK2 inhibitors. The most potent compound for VRK1 (26) displayed an IC50 value of 150 nM and was fairly selective in a panel of 48 human kinases (selectivity score S(50%) of 0.04). Differences in compound binding mode and substituent preferences between the two VRKs were identified by the structure-activity relationship combined with the crystallographic analysis of key compounds. We expect our results to serve as a starting point for the design of more specific and potent inhibitors against each of the two VRKs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available